Controlling inflammation is crucial in managing osteoarthritis in dogs

Canine osteoarthritis (OA) is more than just about pain, it is also a disease of inflammation1,2. Inflammatory mediators such as PGE2 play a pivotal role in OA pathogenesis and disease progression. Increased PGE2 in the joint leads to central sensitisation, which if left untreated can result in heightened pain sensation and chronic pain, i.e. hyperalgesia and allodynia. Chronic pain can be extremely difficult to treat with serious animal welfare implications.

NSAIDs are the cornerstone of managing OA pain & inflammation

Because they manage both inflammation and pain, NSAIDs have historically been, and currently remain, an effective treatment option for dogs with osteoarthritis.

But not all NSAIDs are the same. Specifically designed for canine OA, Galliprant™ selectively blocks only the EP4 receptor to effectively control both pain and inflammation associated with osteoarthritis in dogs. It is the ONLY NSAID to offer this targeted approach, so unlike COX-inhibiting NSAIDs, Galliprant conserves the production of important house-keeping prostaglandins involved in GIT and renal homeostasis. The benefits of this targeted mode of action are highlighted by the results of a Target Animal Safety study³. In this study, Galliprant was administered at up to 10 times the maximum therapeutic dose daily for 9 months. Even at these high daily doses for an extended period of time, Galliprant was well-tolerated - all dogs completed the study in a clinically normal fashion, with no evidence of GI tract ulceration and no kidney or liver problems.

Your trusted choice for the relief of both pain & inflammation in dogs

Galliprant doesn’t just mask the pain of OA; by blocking the EP4 receptor it targets the key receptor involved in pain and inflammation. The unfortunate reality of OA is that there is no cure, which means long-term treatment is the best course of action to make patients more comfortable. Galliprant has been shown to be effective at improving pain interference, pain severity, quality of life and veterinary assessments⁴.

If you’ve been searching for a safe and effective NSAID to treat both early and long-term cases of OA, then look no further. Galliprant has been firmly established as an excellent first-line option in the treatment of canine OA, already improving the quality of life for hundreds of thousands of dogs across the world.

“Osteoarthritis (OA) is one of the leading chronic morbidities in dogs and can affect patients of all ages. There is no cure for osteoarthritis and management centres around control of pain, improving mobility and minimising disease progression. This is accomplished through diet and weight management, targeted nutritional supplementation, rehabilitation therapy by a qualified professional, and judicious use of appropriate pharmaceuticals. Galliprant is one such pharmaceutical, that represents a new age of targeted therapy for managing conditions such as OA. I have found it particularly useful in young patients with conditions such as hip and elbow dysplasia where it is often the first medication I will try for patients requiring longer term management.” 

Dr. Stephen Fearnside BVSc (Hons) FANZCVS (Surgery) DACVSMR MANZCVS (VSMR)
Specialist in Small Animal Surgery
Small Animal Specialist Hospital

Read product leaflet for full instructions. The following mild and generally transient adverse reactions have been observed in dogs treated with grapiprant: vomiting, diarrhoea, inappetance and lethargy. For long-term treatment, appropriate monitoring is recommended. The safety of Galliprant has not been established in dogs less than 3.6 kg or less than 9 months of age.

References:

1. Attur M, Al-Mussawir HE, Patel J, et al. Prostaglandin E2 exerts catabolic effects in osteoarthritis cartilage: Evidence for signaling via the EP4 receptor. J Immunol. 2008; 181:5082-8.
2. Jang Y, Kim M, Hwang SW. Molecular mechanisms underlying the actions of arachidonic acid-derived prostaglandins on peripheral nociception. J Neuroinflammation. 2020;17(1):1-27.
3. Rausch-Derra LC, et al. Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritic pain and inflammation, in healthy dogs. AJVR 2015; 76:853-859.
4. Rausch-Derra LC, et al. A Prospective, Randomized, Masked, Placebo-Controlled Multisite Clinical Study of Grapiprant, an EP4 Prostaglandin Receptor Antagonist (PRA), in Dogs with Osteoarthritis. JVIM 2016; 30:756-763.

For further information contact: 1800 995 709 from anywhere in Australia Monday to Friday or email productsupportau@elancoah.com. Galliprant and Elanco diagonal bar logo are trademarks of Elanco or its affiliates. ©2023 Elanco or its affiliates. PM-AU-23-0567.